Lineage Cell Therapeutics, Inc.
LCTX
$0.483
-$0.017-3.40%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 2.87M | 3.78M | 1.41M | 1.44M | 2.09M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.87M | 3.78M | 1.41M | 1.44M | 2.09M |
| Cost of Revenue | 3.58M | 3.21M | 2.91M | 3.11M | 4.16M |
| Gross Profit | -709.00K | 570.00K | -1.50M | -1.66M | -2.07M |
| SG&A Expenses | 4.40M | 4.41M | 4.36M | 5.00M | 758.00K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.98M | 7.62M | 7.28M | 8.11M | 4.92M |
| Operating Income | -5.11M | -3.84M | -5.87M | -6.66M | -2.83M |
| Income Before Tax | -3.25M | -3.00M | -5.77M | -6.56M | -4.71M |
| Income Tax Expenses | -- | -- | -- | -- | 0.00 |
| Earnings from Continuing Operations | -3.25M | -3.00M | -5.77M | -6.56M | -4.71M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -23.00K | -33.00K | 13.00K | 16.00K | -61.00K |
| Net Income | -3.27M | -3.03M | -5.76M | -6.54M | -4.78M |
| EBIT | -5.11M | -3.84M | -5.87M | -6.66M | -2.83M |
| EBITDA | -4.96M | -3.70M | -5.73M | -6.49M | -2.66M |
| EPS Basic | -0.01 | -0.02 | -0.03 | -0.04 | -0.03 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.02 | -0.02 | 0.00 |
| EPS Diluted | -0.01 | -0.02 | -0.03 | -0.04 | -0.03 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.02 | -0.02 | 0.00 |
| Average Basic Shares Outstanding | 240.19M | 188.84M | 188.81M | 182.91M | 175.01M |
| Average Diluted Shares Outstanding | 240.19M | 188.84M | 188.81M | 182.91M | 175.01M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
